ClinicalTrials.gg
RecruitingNCT07096960START/ESCADAUpdated Jul 31, 2025

Implementation of the START Intervention in Brazil: a Controlled Feasibility Trial

An interventional study of STrAtegies for RelaTives (START) - Brazilian version in Caregiver Burden of People With Dementia, sponsored by Hospital Alemão Oswaldo Cruz. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Hospital Alemão Oswaldo Cruz · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This controlled trial aims to assess the feasibility of a culturally adapted Brazilian version of the START (STrAtegies for RelaTives) program, a structured coping strategy program designed for family caregivers of people living with dementia. The program will be delivered by trained community general health workers (CGHW) in 10 municipalities across Brazil. Outcomes will include measures of feasibility and acceptability, as well as caregiver burden, mental health, and quality of life, assessed at baseline and after 6 months.

Read the detailed description

This study will evaluate the feasibility of the START program in the Brazilian Unified Health System (SUS). The intervention was translated and culturally adapted through a structured process that included expert review and focus groups with mental health professionals and community general health workers (CGHW) to ensure the clarity and cultural relevance of the materials.

The intervention will be delivered by trained CGHW to family caregivers of people living with dementia. CGHW will undergo a 16-hour, in-person training provided by the research team. During the period of the intervention, they will receive ongoing remote supervision to support protocol adherence and address challenges encountered in the field.

Ten municipalities-two from each of the five geographical regions of Brazil-will participate. In each municipality, two primary care units (PCU) will be randomly allocated to either the intervention or the waitlist control group.

The selection of participating municipalities will be conducted in collaboration with each state's Bipartite Inter-managerial Commission (Comissão Intergestora Bipartite, CIB). Municipalities will be eligible if they have ≥100,000 inhabitants and agree to participate. Each will be required to list all PCU with ≥15 dementia diagnoses (ICD-10). If a municipality does not have at least two PCU meeting this threshold, units with ≥10 diagnoses may be considered. From this list, two PCU will be randomly drawn. Eligible pairs must meet two conditions: (1) they must be non-contiguous, and (2) their populations must be demographically similar, as assessed by local authorities. If these two criteria are not met, a new draw will be conducted.

Feasibility and acceptability will be assessed as primary outcomes through operational indicators (e.g., number of sessions completed, adherence, dropouts), structured online questionnaires completed by caregivers and CGHW, and semi-structured qualitative interviews conducted with caregivers, CGHW, and municipal health managers.

Secondary outcomes will include caregiver burden, mental health symptoms, quality of life, coping strategies, and neuropsychiatric symptoms of the care recipient. These outcomes will be measured at baseline and again six months after the intervention using validated instruments including the HADS, ZBI, WHOQOL-Bref, Brief COPE, and NPI.

Intervention fidelity will be assessed through randomly selected audio recordings of sessions and structured checklists completed by independent researchers.

02

Conditions studied

  • Caregiver Burden of People With Dementia
03

In context

Caregiver Burden

503 studies on the registry are indexed under Caregiver Burden; 166 are open to participants now.

This study's planned enrollment of 90 is above the median of 73 across 404 interventional studies indexed under Caregiver Burden.

Browse Caregiver Burden studies →

Lead sponsor

Hospital Alemão Oswaldo Cruz is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Informal caregivers (≥18 years old) who are the primary or one of the primary persons responsible for caring for a family member with dementia, providing regular and sustained emotional or practical support every week, and living in the same household or nearby with frequent face-to-face interaction.
  • Care recipient (person with dementia) with Clinical Dementia Rating (CDR) score ≥1.
  • Care recipient with at least one ICD-10 dementia diagnosis code documented in their medical record.

Exclusion criteria

Exclusion criteria:

  • Illiterate caregivers.
  • Caregivers who provide only occasional or sporadic support (less than weekly or without regular caregiving responsibility).
  • Care recipients who are institutionalized (e.g., living in long-term care facilities).
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    START/ESCADA Intervention

    Participants will receive the culturally adapted Brazilian version of START (ESCADA).

    Behavioral: STrAtegies for RelaTives (START) - Brazilian version

  • No intervention
    Waitlist Control

    Participants receive usual care and will be offered the START/ESCADA intervention after 6 months at the end of the study.

Interventions

  • BehavioralSTrAtegies for RelaTives (START) - Brazilian version

    Eight individualized, weekly, home-based sessions will be delivered by trained community general health workers (CGHW). The intervention includes coping strategies, behavior management, and communication skills. Caregivers receive printed materials and structured exercises. CGHW receive a facilitator manual.

06

What researchers measure

Primary outcomes

  1. Feasibility questionnaire

    Feasibility of the START/ESCADA intervention assessed through an online structured questionnaire applied to caregivers and community health workers (CHW), covering domains of acceptability, demand, implementation, practicality, adaptation, integration, and expansion.

    Time frame: Approximately 8 weeks post-baseline (after completing the intervention)

  2. Operational feasibility metrics

    Number of caregivers who consented to participate; number and proportion who completed all 8 sessions; average number of weeks to complete 8 sessions; number and proportion of community health workers (CHW) completing training; number of CHW delivering the intervention.

    Time frame: Approximately 8 weeks post-baseline (after completing the intervention)

  3. Qualitative feasibility interviews

    Feasibility and acceptability of the START/ESCADA intervention assessed via semi-structured qualitative interviews with managers of primary care units, general health workers (ACS), and caregivers, exploring domains such as acceptability, demand, implementation, practicality, adaptation, integration, and expansion.

    Time frame: Approximately 8 weeks post-baseline (after completing the intervention)

Secondary outcomes

  1. Caregiver burden

    Zarit Burden Interview (ZBI), 22-item version; total score ranges from 0 to 88, with higher scores indicating greater caregiver burden.

    Time frame: 6 months post-baseline

  2. Anxiety and depression

    Hospital Anxiety and Depression Scale (HADS); two subscales (Anxiety, Depression), each ranging from 0 to 21; higher scores indicate greater anxiety or depressive symptoms.

    Time frame: 6 months post-baseline

  3. Quality of life (caregiver)

    World Health Organization Quality of Life Instrument - Short Form (WHOQOL-BREF); includes four domain scores (Physical Health, Psychological, Social Relationships, Environment), each transformed to a scale from 0 to 100; higher scores indicate better quality of life.

    Time frame: 6 months post-baseline

  4. Coping strategies

    Brief COPE Inventory; 28 items grouped into 14 subscales (coping strategies), each subscale scored by summing two items (range 2 to 8); higher scores indicate greater use of the specific coping strategy.

    Time frame: 6 months post-baseline

  5. Neuropsychiatric symptoms

    Neuropsychiatric Inventory (NPI); assesses 12 neuropsychiatric domains in dementia patients. Each domain score is calculated by multiplying frequency (1-4) by severity (1-3), with domain scores ranging from 0 to 12. The total NPI score ranges from 0 to 144, with higher scores indicating greater neuropsychiatric symptom burden.

    Time frame: 6 months post-baseline

  6. Use of health and social care resources

    Structured questionnaire

    Time frame: 6 months post-baseline

07

Study locations

1 of 1 sites recruiting
  • Lucas Martins Teixeira
    Vitória, Espírito Santo, Brazil
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Aug 2026, 13 months after the start.

Of 285 non-industry interventional studies with no phase under Caregiver Burden, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's planned 13 months is below that.

Counting every sponsor, half of 294 studies reached it within 16 months; a quarter within 7 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2025
First posted
Jul 31, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Aug 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07096960
Lead sponsor
Hospital Alemão Oswaldo Cruz
Collaborators
University College, London, Ministry of Health, Brazil
Responsible party
Lucas Martins Teixeira (Principal Investigator, Hospital Alemão Oswaldo Cruz) — Principal investigator
First posted
Jul 31, 2025
Start date
Jul 1, 2025
Primary completion
Aug 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 31, 2025

Study contacts

Lucas Martins Teixeira
Contact
lucas.martins@haoc.com.br
+55 86 999137014

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion